Intravitreal injection of bevacizumab was effective in two cases of Irvine-Gass syndrome

Yukari Shirakata, Chieko Shiragami, Hiroyuki Nomoto, Takashi Fujimura, Fumio Shiraga

Research output: Contribution to journalArticle


Purpose : To report two cases of Irvine-Gass syndrome that responded to intravitreal injection of bevacizumab. Cases and Findings : Two males, aged 73 and 69 years, received phacoemulsification with intraocular lens implantation. Visual acuity improved to 0.8 and 1.2 but decreased to 0.2 and 0.6 after 3 weeks and 2 months respectively. Both cases showed cystoid macular edema (CME) and thickened fovea, leading to the diagnosis of Irvine-Gass syndrome. Intravitreal injection of bevacizumab was followed by resolution of CME after 2 and 1 week respectively. Visual acuity improved to 0.4 and 1.2 respectively. There has been no recurrence for 13 and 22 months until present. Conclusion : Intravitreal injection of bevacizumab may be effective for Irvine-Gass syndrome.Rinsho Ganka (Jpn J Clin Ophthalmol) 63(5): 801-805, 2009.

Original languageEnglish
Pages (from-to)801-805
Number of pages5
JournalJapanese Journal of Clinical Ophthalmology
Issue number5
Publication statusPublished - Aug 5 2009
Externally publishedYes


ASJC Scopus subject areas

  • Ophthalmology

Cite this